Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Complementary and alternative medicine in multiple sclerosis.
The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation.
Benign Multiple Sclerosis: Does it exist?
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Vitamin A and systemic inflammation as protective factors in multiple sclerosis.
Editorial for JNV issue on PML.
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Demyelination: the role of reactive oxygen and nitrogen species.
Don't stress about it!: Is stress management a disease-modifying therapy for multiple sclerosis?
Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis.
Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
Amiloride Clinical Trial In Optic Neuritis (ACTION)
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Multiple sclerosis and breast cancer.
A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
Multiple sclerosis: Risk of comorbid inflammatory diseases in MS might not be genetically determined.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Therapeutic effect of ghrelin in experimental autoimmune encephalomyelitis by inhibiting antigen-specific Th1/Th17 responses and inducing regulatory T cells.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].

Pages